Open access · OA
via OpenAlex
Epigenetic control of lipid metabolism: implications for lifespan and healthspan
Gabriele G. Schiattarella, Joseph A. Hill
Cardiovascular Research · 2018 · ▲ 2 citations
Epigenetic alterations
Mitochondrial dysfunction
Cellular senescence
Disabled macroautophagy
C. elegans
Human
Mouse
Preclinical / animal
Abstract
Dr. Gabriele G. Schiattarella is a researcher at the University of Texas Southwestern Medical Center in Dallas, TX, USA. He received his MD in 2009 from the University Federico II of Naples (Italy). After completing a fellowship in Cardiology at the same university (2015) and matriculating in a PhD programme in Experimental Medicine, he moved to UT Southwestern Medical Center where he completed his PhD programme. Dr. Schiattarella’s background is in medicine, experimental cardiology and cellular/molecular biology, with specific training and expertise in murine models of cardiovascular disease and preclinical assessment of cardiovascular function. His research interests include metabolic regulation of cardiac remodelling and failure (HFpEF and HFrEF), mitochondrial dysfunction(definition), autophagy(definition) and epigenetics. Dr. Schiattarella has received numerous research awards including travel awards from the Council on Basic Cardiovascular Science of the European Society of Cardiology (2009–10), the Research Award for Young Investigator of the Italian Society of Cardiology (2011) and the STAR Award—Young Researcher Mobility of the University Federico II of Naples (2015). Dr. Joseph A. Hill is a cardiologist-scientist whose research focuses on molecular mechanisms of remodelling in the disease-stressed myocardium. He graduated with an MD, PhD from Duke University. Next, hepursued postdoctoral scientific training at the Institut Pasteur in Paris, followed by clinical training in Internal Medicine and Cardiology at the Brigham and Women’s Hospital, Harvard Medical School. Dr. Hill served on the faculty of the University of Iowa for 5 years before moving in 2002 to the University ofTexas Southwestern Medical Center to assume the role of Chief of Cardiology and Director of the Harry S. Moss Heart Center. Dr. Hill’s research group strives to decipher mechanisms of structural, functional,metabolic, and electrical remodelling in heart disease with an eye toward therapeutic intervention. He hasreceived numerous recognitions and awards, including election to the Association of American Professors; he recently served as President of the Association of University Cardiologists and chair of the Academic Council of the American College of Cardiology. Dr. Hill received the 2018 Research Achievement Award from the International Society for Heart Research. Presently, he serves as Editor-in-Chief of Circulation. Commentary on ‘Mono-unsaturated fatty acids link H3K4me3 modifiers to C. elegans lifespan’ by Han et al., Nature 2017.1 Improvements in prevention and treatment of cardiovascular diseases (CVD) have resulted in a meaningful decline in cardiovascular mortality and increased life expectancy in industrialized countries.2 However, aging of the global population, coupled with the success of cardiovascular prevention and therapeutic intervention, have culminated in increasing prevalence of chronic heart disease.3 Thus, we have witnessed over the last 40 years a progressive shift in the delicate balance between lifespan and healthspan(definition). Aging is one of the most powerful disease risk factors, especially for CVD.4 In contrast with other risk factors, such as high blood pressure or smoking, aging is a ‘non-modifiable’ risk factor. This implies that nothing can be done to arrest senescence(definition). Despite this, considerable effort has been directed at slowing the aging process. Indeed, a number of interventions in preclinical and clinical settings have been proposed to increase lifespan.4 The global epidemic of obesity remains among the greatest contemporary challenges in cardiovascular medicine.5 Obesity has powerfully detrimental effects on cardiovascular health. That said, the association between fat and cardiovascular risk has not been fully elucidated. Epidemiological studies have shown that excess body mass index (BMI) is associated with substantially shorter healthy lifespan.6 Although, BMI is the most commonly used parameter to gauge adiposity, limitations in its interpretation are well established. Interestingly, fat accumulation increases lifespan in invertebrates and lower mammals.7 However, how lipids influence lifespan remains unclear. Epigenetic regulation is a major mechanism governing numerous cellular processes. Histone modifications are susceptible to metabolic changes, as most of the enzymes involved in chromatin remodelling use metabolic substrates as cofactors.8 For example, α-ketoglutarate, an intermediate of the Kreb’s cycle, is required for the function of certain histone methyltransferases as well as cytosine hydroxylation, a reaction mediated by TET (ten eleven translocation) enzymes. Given the robust relationship between metabolic changes and epigenetic control, attempts have been made to decipher how these processes influence each other. Recent work by Han et al.1 provides compelling insights into how lipid metabolism, histone methylation, and lifespan are intricately linked. Trimethylation (m3) of lysine 3 (K3) on histone 4 (H4) (H4K3me3) is an epigenetic mark indicative of active chromatin sites; it is associated with increased accessibility of chromatin structure and consequent increases in transcription. In worms and mammals, loss of function of H4K3 methyltransferase is associated with increased lifespan.9 In the present study, the authors discovered that inactivation of the H4K3 methyltransferase complex in worms positively influences fat deposition and increases fat storage. In search of the specific lipid class that accumulates, the authors identified the accretion of mono-unsaturated fatty acids (MUFAs) as a specific lipid signature in long-lived worms. Accumulation of MUFAs in H4K3 methyltransferase-deficient worms was dependent on specific upregulation of FAT7, a MUFA synthetic enzyme, suggesting that modification of the H3K4 methylation landscape impacts lipid metabolism. Going forward, the investigators were able to show that H3K4me3 methyltransferase deficiency in worms leads to reduction in
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1093/cvr/cvy048
- Canonical
- link ↗
- Fetched
- 2026-10-22 MST
Cite this
APA
Schiattarella, G.G., & Hill, J.A. (2018). Epigenetic control of lipid metabolism: implications for lifespan and healthspan. <em>Cardiovascular Research</em>. https://doi.org/10.1093/cvr/cvy048
Vancouver
Schiattarella GG, Hill JA. Epigenetic control of lipid metabolism: implications for lifespan and healthspan. Cardiovascular Research. 2018. doi:10.1093/cvr/cvy048.
BibTeX
@article{gabriele2018Epigen,
title = {Epigenetic control of lipid metabolism: implications for lifespan and healthspan},
author = {Gabriele G. Schiattarella and Joseph A. Hill},
journal = {Cardiovascular Research},
year = {2018},
doi = {10.1093/cvr/cvy048},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Expert Review of Respiratory Medicine 2019
Citation only
Accelerated lung aging and chronic obstructive pulmonary disease
Biology of the Cell 2019
Preprint · CC-BY
Targeting of the unfolded protein response (UPR) as therapy for Parkinson's disease
Biochemical Society Transactions 2022
Open access · CC-BY
Fundamental roles for inter-organelle communication in aging
Stem Cell Research & Therapy 2025
Open access · CC-BY
Extracellular vesicles in age-related diseases: disease pathogenesis, intervention, and biomarker
Frontiers in Science 2026
Open access · CC-BY
The GPCR-ome as a central regulator of human healthspan
Signal Transduction and Targeted Therapy 2022
Open access · CC-BY